By Chris Wack
Firefly Neuroscience shares doubled to $3.90 Tuesday after the company said it is advancing its research used to assess a patient's brain age--an estimation of the biological age of a person's brain--via its Food and Drug Administration-cleared BNA technology platform.
The AI healthcare company said the technology demonstrated the ability to harness resting electroencephalograms and cognitive electroencephalograms data to assess patients' brain age.
Firefly said the BNA technology has the potential to show various facets of human brain aging. BNA data assessment, the company said, could find a significant disparity between brain age and chronological age, which could serve as a valuable risk factor for dementia.
Firefly said it hopes to apply the technology to early screening and monitoring for Alzheimer's patients.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 14, 2025 10:57 ET (15:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.